Antibodies that bind cell-associated CA 125/O772P and...

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S130100, C424S141100, C424S178100, C424S181100, C530S387100, C530S387900, C530S388100, C530S388800

Reexamination Certificate

active

10687035

ABSTRACT:
The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a CA 125/O772P-related disorder. In particular, the present invention provides methods of preventing, managing, treating, or ameliorating one or more symptoms associated with a cell proliferative disorder, such as cancer, e.g., ovarian cancer. The present invention still further provides methods for diagnosing a CA 125/O772P-related disorder or predisposition to developing such a disorder, as well as methods for identifying antibodies, and antigen-binding fragments of antibodies, that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides.

REFERENCES:
patent: 4921790 (1990-05-01), O'Brien
patent: 5059680 (1991-10-01), Davis et al.
patent: 5366866 (1994-11-01), Xu et al.
patent: 5486456 (1996-01-01), Xu et al.
patent: 5650291 (1997-07-01), Lee
patent: 5693762 (1997-12-01), Queen et al.
patent: 5858361 (1999-01-01), Wagner et al.
patent: 5871941 (1999-02-01), Auersperg
patent: 5976818 (1999-11-01), O'Brien
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6241985 (2001-06-01), Madiyalakan et al.
patent: 6376654 (2002-04-01), Gelber
patent: 6468546 (2002-10-01), Mitcham et al.
patent: 6488931 (2002-12-01), Mitcham et al.
patent: 6528253 (2003-03-01), Mitcham et al.
patent: 6670463 (2003-12-01), Mitcham et al.
patent: 6699664 (2004-03-01), Mitcham et al.
patent: 2002/0009451 (2002-01-01), O'Brien
patent: 2002/0022591 (2002-02-01), Algate et al.
patent: 2002/0037287 (2002-03-01), Gelber
patent: 2002/0081609 (2002-06-01), Dillon et al.
patent: 2002/0119158 (2002-08-01), Algate et al.
patent: 2003/0008299 (2003-01-01), Algate
patent: 2003/0082655 (2003-05-01), O'Brien
patent: 2003/0091580 (2003-05-01), Mitcham et al.
patent: 2003/0104442 (2003-06-01), Lloyd et al.
patent: 2003/0124140 (2003-07-01), Bangur et al.
patent: 2003/0165504 (2003-09-01), Retter et al.
patent: 2004/0127401 (2004-07-01), O'Brien
patent: 0 332 651 (1996-12-01), None
patent: 1256354 (2002-11-01), None
patent: WO89/01629 (1989-02-01), None
patent: WO94/27637 (1994-08-01), None
patent: WO96/31539 (1996-10-01), None
patent: WO00/36107 (2000-06-01), None
patent: WO 00/36107 (2000-06-01), None
patent: WO0036107 (2000-06-01), None
patent: WO01/40269 (2001-06-01), None
patent: WO01/60860 (2001-08-01), None
patent: WO0157207 (2001-08-01), None
patent: WO01/70804 (2001-09-01), None
patent: WO01/70979 (2001-09-01), None
patent: WO01/75177 (2001-10-01), None
patent: WO01/85203 (2001-11-01), None
patent: WO02/00677 (2002-01-01), None
patent: WO0206317 (2002-01-01), None
patent: WO0207783 (2002-01-01), None
patent: WO02/071928 (2002-09-01), None
patent: WO02/074961 (2002-09-01), None
patent: WO02/076384 (2002-10-01), None
patent: WO02083866 (2002-10-01), None
patent: WO02/092836 (2002-11-01), None
patent: WO02092836 (2002-11-01), None
patent: WO03076465 (2003-09-01), None
patent: WO03076473 (2003-09-01), None
patent: WO2004005470 (2004-01-01), None
patent: WO2004045553 (2004-06-01), None
patent: PCT/US03/32945 (2004-08-01), None
(American Heritage Dictionary of the English Language, 4th Ed., 2000, p. 1-2).
(MSN Encarta, Dictionary, p. 1-2).
Berger et al (Cancer Biotherapy & Radiopharmaceuticals, 2005, 20:589-602).
Janeway et al (Immunobiology, 2001, 5th Ed., Garland Publishing, New York).
(Rudikoff et al, PNAS, USA, 1982, 79: 1979).
Yin and Lloyd, Journal of Biological Chemistry, Jul. 2001, 276:27371-27375.
O'Brien et al (Tumour Biol, 2001, 22:348-66).
Bast et al. (1981) “Reactivity of a Monoclonal Antibody with Human Ovarian Cacrcin”J. Clin Invest68(5): 1331-37.
Boshell et al. (1992) “The Product of the Human MUC1 Gene When Secreted by Mouse Cells Transfected With the Full-Length cDNA Lacks Cytoplasmic Tail”Biocehm and Biophys Res. Comm185(1):1-8.
Frailes et al. (1993) “Purification and Characterization of the CA 125 Tumor-Associated Antigen From Human Ascites” Tumour Biol. 1993;14(1):18-29.
Gadducci et al., (1992) :“The Concomitant Determination of Different Tumor Markers in Patients with Epithelial Ovarian Cancer and Benign Ovarian Masses: Relevance for Differential Diagnosis”,Gynecol Oncol. 44(2):147-54.
Hovig et al. (2001) “CA125: The End of the Beginning”Tumor Bio. 22:345-47.
Hu et al. (2003) “Discovery and Validation of New Molecular Targets of Ovarian Cancer”Current Opinion in Molecular Therapeutics. 5(6):625-630.
Kabawat et al. (1983) “Immunopathologic Characterization of a Monoclonal Antibody That Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell Types”, Am. J. Clin. Pathol. 79:98-104.
Lightenberg et al. (1992) “Cell-Associated Episialin Is a Complex Containing Two Proteins Derived From A Common Precursor”The Journal of Biol. Chem.. 267(9):6171-77.
Madiyalakan et al. (1997) “Ovarex MAb-B43.13:IFN-Gamma Could Improve the Ovarian Tumor Cell Sensitivity to CA125-Specific Allogenic Cytotoxic T Cell”Hybridoma16(1): 41-5.
Maeda et al. (2004) “Solution Structure of the SEA Domain From the Murine Homologue of Ovarian Cancer Antigen CA125 (MUC16)”The Journal of Biol. Chem.. 279(13): 13174-13182.
Noujaim et al. (2001) “Induction of CA125-Specific B and T Cell Responses in Patients Injected With MAb-B43.13—Evidence for Antibody-Mediated Anti-processing and Presentation of CA125 in Vivo”Cancer Biother. Radiopharm16(3): 187-203.
Nustad et al. (1996) “Specificity and Affinity of 26 Monoclonal Antibodies Against the CA 125 Antigen: First Report From the ISOBM TD-1 Workshop. International Society for Oncodevelopmental Biology and Medicine”Tumour Biol. 17(4): 196-219.
Nustad et al. (2002) “Epitopes on CA 125 From Cervical Mucus and Ascites Fluid and Characterization of Six New Antibodies. Third report from the ISOBM TD-1 workshop”Tumour Biol. 23(5): 303-314.
O'Brien et al. (2001) “The CA125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences”Tumor Bio. 22:348-366.
O'Brien et al. (2002) “The CA125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure”Tumor Bio. 23:154-169.
Saga et al. (1990) “Construction of an Immunoradiometric Assay for Ovarian Cancer Antigen CA125 Recognizing Different Antigenic Determinant”Acta Obstet Gynecol. Scand. 69(2):175-81.
Saga et al. (1990) “An Antibody-Tumor Model for the Targeting of CA125-Producing Gynecologic Malignancies”Jpn J. Cancer Res.. 81(11):1141-48.
Yin et al. (2001) “Molecular Cloning of the CA125 Ovarian Cancer Antigen”The Journal of Biol. Chem. 276(29):27371-375.
Andersson, et al., 1999 “Biokinetics of the Monoclonal Antibodies MOv 18, OV 185 and OV 197 Labelled with125I According to the m-MeATE Method or the Iodogen Method in Nude Mice with Ovarian Cancer Xenografts” ,ACTA Oncologica, 38(3) 323-328.
Bouvier, et al., 1988 “Serum Levels of Tumor Markers and Presence of Human Antimouse Antibodies: Implications for Diagnosis and Treatment with Radiolabeled Monoclonal Antibodies”,Cancer Detection and Prevention, 13: 251-262.
Chatal, et al., 1989 “Biodistribution of Indium-111-Labeled OC 125 Monoclonal Antibody Intraperitoneally Injected Into Patients Operated On for Ovarian Carcinomas”,Cancer Research, 49: 3087-3094.
Cuesta, et al., 1999 “Tissue Quantifications of CA 125 in Epithelial Ovarian Cancer”,The International Journal of Biological Markers, 14(2): 106-114.
Gaetje, et al., 1999 “Ovarian Cancer Antigen CA 125 Enhances the Invasiveness of the Endometriotic Cell Line EEC 145”,J. Soc. Gynecol. Invest., 6(5): 278-281.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antibodies that bind cell-associated CA 125/O772P and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies that bind cell-associated CA 125/O772P and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that bind cell-associated CA 125/O772P and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3925015

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.